AU2003251949A1 - Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype - Google Patents

Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype

Info

Publication number
AU2003251949A1
AU2003251949A1 AU2003251949A AU2003251949A AU2003251949A1 AU 2003251949 A1 AU2003251949 A1 AU 2003251949A1 AU 2003251949 A AU2003251949 A AU 2003251949A AU 2003251949 A AU2003251949 A AU 2003251949A AU 2003251949 A1 AU2003251949 A1 AU 2003251949A1
Authority
AU
Australia
Prior art keywords
alpha
therapeutic
adrenergic receptor
screening methods
receptor subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251949A
Inventor
Lee Eberhardt Limbird
Christopher Michael TAN
Matthew Hunter Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2003251949A1 publication Critical patent/AU2003251949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003251949A 2002-07-18 2003-07-17 Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype Abandoned AU2003251949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39698002P 2002-07-18 2002-07-18
US60/396,980 2002-07-18
PCT/US2003/022209 WO2004009090A1 (en) 2002-07-18 2003-07-17 Therapeutic and screening methods employing partial agonism of the ∝-2a adrenergic receptor subtype

Publications (1)

Publication Number Publication Date
AU2003251949A1 true AU2003251949A1 (en) 2004-02-09

Family

ID=30770969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251949A Abandoned AU2003251949A1 (en) 2002-07-18 2003-07-17 Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype

Country Status (2)

Country Link
AU (1) AU2003251949A1 (en)
WO (1) WO2004009090A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US11590107B2 (en) * 2019-10-25 2023-02-28 Curasen Therapeutics, Inc. Methods for treating neurological disorders with α1A-AR partial agonists
US20240002369A1 (en) * 2020-11-12 2024-01-04 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721978D0 (en) * 1997-10-17 1997-12-17 Lilly Co Eli Treatment of depression

Also Published As

Publication number Publication date
WO2004009090A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
AU2003214873A1 (en) Methods of treating conditions associated with an edg receptor
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003298998A1 (en) Oriented nanostructures and methods of preparing
AU2003251970A8 (en) Modulators of the glucocorticoid receptor and method
SI1521733T1 (en) Modulators of the glucocorticoid receptor
ZA200501308B (en) Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction
AU2003202542A1 (en) Ligand for g-protein coupled receptor gpr43 and uses thereof
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003286737A1 (en) Apparatuses and methods for the manufacture and placement of truss assemblies
AU2003279841A1 (en) Uses of human zven antagonists
AU2003239610A8 (en) Tiled biochips and the methods of making the same
AU2003278814A1 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
AU2003295500A1 (en) Nuclear receptor-based diagnostic, therapeutic, and screening methods
AU2003224956A1 (en) Reference structures and reference structure enhanced tomography
AU2003300904A1 (en) Antagonists for human prolactin
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003251949A1 (en) Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype
AU2003236649A1 (en) Egf receptor antagonists in the treatment of gastric cancer
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
AU2002353163A1 (en) Scatterometry structure with embedded ring oscillator, and methods of using same
EP1517879A4 (en) Aminoalkylphenols, methods of using and making the same
AU2003273152A1 (en) Receptor and screening methods
AU2003300867A8 (en) Uses of the snorf207 receptor
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease
AU2003219424A1 (en) Methods of using alpha 1b-adrenergic receptors